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Julien.Ducry@h-fr.chSummaryEctopic ACTH Cushing’s syndrome (EAS) is often caused by neuroendocrine tumors (NETs) of lungs, pancreas, thymus, and
other less frequent locations. Localizing the source of ACTH can be challenging. A 64-year-old man presented with rapidly
progressing fatigue, muscular weakness, and dyspnea. He was in poor condition and showed facial redness, proximal
amyotrophy, and bruises. Laboratory disclosed hypokalemia, metabolic alkalosis, and markedly elevated ACTH and
cortisol levels. Pituitary was normal on magnetic resonance imaging (MRI), and bilateral inferior petrosal sinus blood
sampling with corticotropin-releasing hormone stimulation showed no significant central-to-periphery gradient of ACTH.
Head and neck, thoracic and abdominal computerized tomography (CT), MRI, somatostatin receptor scintigraphy (SSRS), and
18F-deoxyglucose-positron emission tomography (FDG-PET) failed to identify the primary tumor. 18F-dihydroxyphenylalanine
(F-DOPA)-PET/CT unveiled a 20-mm nodule in the jejunum and a metastatic lymph node. Segmental jejunum resection
showed two adjacent NETs, measuring 2.0 and 0.5 cm with a peritoneal metastasis. The largest tumor expressed ACTH in 30%
of cells. Following surgery, after a transient adrenal insufficiency, ACTH and cortisol levels returned to normal values and
remain normal over a follow-up of 26 months. Small mid-gut NETs are difficult to localize on CTor MRI, and require metabolic
imaging. Owing to low mitotic activity, NETs are generally poor candidates for FDG-PET, whereas SSRS shows poor sensitivity
in EAS due to intrinsically low tumor concentration of type-2 somatostatin receptors (SST2) or to receptor down regulation by
excess cortisol. However, F-DOPA-PET, which is related to amine precursor uptake by NETs, has been reported to have high
positive predictive value for occult EAS despite low sensitivity, and constitutes a useful alternative to more conventional
methods of tumor localization.Learning points:
† Uncontrolled high cortisol levels in EAS can be lethal if untreated.
† Surgical excision is the keystone of NETs treatment, thus tumor localization is crucial.
† Most cases of EAS are caused by NETs, which are located mainly in the lungs. However, small gut NETs are elusive to
conventional imaging and require metabolic imaging for detection.
† FDG-PET, based on tumor high metabolic rate, may not detect NETs that have low mitotic activity. SSRS may also fail,
due to absent or low concentration of SST2, which may be down regulated by excess cortisol.
† F-DOPA-PET, based on amine-precursor uptake, can be a useful method to localize the occult source of ACTH in EAS
when other methods have failed.http://www.edmcasereports.com
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Ectopic ACTH Cushing’s syndrome (EAS), accounting for
5–10% of all cases of Cushing’s syndrome, is mainly
caused by neuroendocrine tumors (NETs) of lungs,
pancreas, thymus, or tumors arising in other, less frequent
sites (1). After ruling out a pituitary origin, the task to
localize the source of ACTH can be challenging due to
small tumor size and lack of specificity of computed
tomography (CT)-scan and magnetic resonance imaging
(MRI). Thus, diagnostic modalities based on tumor biology
need to be used.
As epithelial-derived tumors arising in different organs
and displaying predominant neuroendocrine differen-
tiation, NETs share both organ-characteristic and neuro-
endocrine features (2). From a clinicopathological stand
point, they range from benign neoplasms to rapidly
progressing hormone-secreting carcinomas, and from
occult to large symptomatic tumors (3). Functional
diagnostic modalities include: i) somatostatin receptor
scintigraphy (SSRS) with 111Indium-Pentetreotide or with
68Gallium-DOTA-TATE-PET takes advantage of the high
concentration of type 2 somatostatin receptors (SST2) that
is commonly observed in NETs; ii) 6-[fluoride 18]fluoro-
dihydroxyphenylalanine-positron emission tomography
(F-DOPA-PET), based on the ability of APUD-derived NETs
to take up, accumulate, and decarboxylate amine
precursors to synthesize, store, and secrete bioactive
substances; and iii) 18F-deoxyglucose-PET (FDG-PET) scan
that aims at imaging glycolytic activity in tumors that
have an elevated metabolic rate (4).
Notwithstanding a frequently indolent course, NETs
display a marked tendency to metastasize and progress (5).
Metastatic tumors may require focal treatment (e.g.
thermal ablation or chemoembolization) or systemic
medical therapy. Somatostatin receptor-targeted radio-
labeled peptides, and therapies based on the inhibition of
tyrosine kinase or mammalian target of rapamycin, have
proven efficacy to slower disease progression (6) (7) (8) (9)
(10). Cytotoxic chemotherapy can also be used in patients
with progressive metastatic disease and no other treat-
ment option (11). In addition, somatostatin receptor
analogues often result in symptomatic relief by hampering
hormone secretion in functional NETs (6). However, at
present time only complete surgical removal offers long-
term remission and cure. Therefore early localization of
newly diagnosed NETs is crucial. In the particular case of
EAS, the intense adrenal response to sustained ACTH may
favor early recognition of the syndrome, but does not
necessarily facilitate the localization of a small responsiblehttp://www.edmcasereports.comtumor. The patient described in this case report presented
with EAS caused by a small ACTH-secreting NET in an
unusual location.Case presentation
A 64-year-old man, newly diagnosed with hypertension,
presented with intense fatigue, muscular weakness, and
shortness of breath (NYHA Stage IV), which rapidly
increased within 4 months. On examination, the patient
was in poor physical condition but hemodynamically
stable without respiratory insufficiency. He showed slight
facial redness, marked proximal limb muscles atrophy,
and mild skin thinning with bruises. There was no moon
face, purple striae, supra-clavicular fat pads, or buffalo
hump. Laboratory data revealed severe hypokalemia
(K 1.7 mmol/l) with metabolic alkalosis (base excess
10.9 mmol/l).Investigation
Confirmation of Cushing’s syndrome
Random plasma cortisol was 1600 nmol/l (normal range
at 1700 h: 40–250 nmol/l), with ACTH 261 ng/l (normal
range at 1700 h: 5–35 ng/l), and urinary free cortisol
9181 nmol/day (normal range: 20–220 nmol/day). Plasma
cortisol level on a 2-day high-dose dexamethasone suppres-
sion test (2 mg/6 h) decreased from 1221 to 721 nmol/l.Investigation of ACTH-dependent Cushing’s syndrome
Pituitary-centered MRI showed no evidence of disease
especially in hypothalamus or pituitary gland. Bilateral
inferior petrosal sinus blood sampling (BIPSS), including
corticotropin-releasing hormone (CRH) stimulation,
showed no significant central-to-periphery ACTH gradient
and ruled-out a pituitary origin of ACTH excess (Table 1).Tumor localization of EAS
Head and neck, thorax, and abdomen 3 mm-sliced CT-scan
and MRI were unremarkable, excepted for moderately
hyperplasic, nonnodular adrenals; SSRS (Fig. 1A) and FDG-
PET/CT (Fig. 1B) failed to localize any functionally active
lesion; finally, F-DOPA-PET/CT scan disclosed a 20 mm
active tumor in the jejunum wall with a possible adjacent
metastatic lymph node (Fig. 1C, D and E).2
Table 1 Bilateral inferior petrosal sinus sampling (BIPSS) results. Plasma cortisol and ACTH levels before and after CRH injection,
1 mg/kg in i.v. bolus.
Time (min)
K15 0 5 10 15 25 35 50 60
Peripheral vein: ACTH (ng/l) 195 223 228 229 229 207 204 184 187
Peripheral vein: cortisol (nmol/l) 1018 983 946 990 951 1037 1054 951 899
IPS left: ACTH (ng/l) 215 259 249 254 252 237 225 207 208
IPS right: ACTH (ng/l) 226 257 274 277 281 257 244 222 241
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Surgical treatment
At laparotomy, a segmental resection of the mid-jejunum
was performed, including adjacent mesenteric lympha-
denectomy. Histopathology revealed two adjacent well-
differenced NETs in the jejunum wall, displaying low
proliferation index (one mitosis per ten high-power fields;
Ki67 1%), classified as WHO and ENETS grade 1 (3). The
largest tumor (2 cm) invaded the whole jejunum wall up
to the serosa, and was associated with a local peritoneal
tumor deposit and with three metastatic lymph nodes out
of five, showing capsular invasion (TNM: pT4 pN1 (3/5)
M1 G1 R0) (3). The immunohistochemistry showed ACTH
expression in 30% of the cells. The adjacent 0.5 cm tumor
invaded the muscularis mucosae only and showed no
vascular invasion and no ACTH expression.Outcome and follow up
Soon after surgery, ACTH and cortisol fell to low levels and
transient adrenal insufficiency required cortisol replace-
ment. The postoperative hospital stay was complicated
on day 9 by a lower limb deep venous thrombosis and
pulmonary embolism. Following anticoagulation, the
patient was discharged uneventfully 5 days later.
The patient fully recovered, and after a follow up of
26 months, ACTH and cortisol levels remain normal and
sequential CT scans show no evidence of recurrence.Figure 1
(A) 111In-octreotide scintigraphy and (B) 18FDG-PET did not reveal any
pathological tracer uptake. (C) 18F-DOPA PET-CT allowed to locate a
primary jejunal tumour (D) (arrow) and revealed metastatic lymph node(s)
(E) (arrowhead).Discussion
Cushing’s syndrome as paraneoplastic syndrome is a
well-known phenomenon associated with NETs. ACTH-
secreting tumors are more commonly encountered with
bronchial carcinoids and small cell lung cancer (12).
Small ACTH-secreting tumors may remain undetected
on anatomic imaging (pituitary MRI, and neck and trunk
CT and MRI), despite clinical and biochemical evidence of
ACTH-dependent Cushing’s syndrome, and noninvasivehttp://www.edmcasereports.comdynamic tests are not always able to distinguish between
Cushing’s disease and EAS due to NETs. In our case, the
intermediate cortisol suppression of 41% on high-dose
dexamethasone was consistent with either possibility, and
BIPSS was necessary to confirm EAS.
Surgery is a key element in therapy, allowing radical
resection of metastases-prone NETs and in the setting of
EAS rapid control of life-threatening cortisol excess, which
can avoid chemical adrenolysis or palliative surgical
adrenalectomy (13). Small abdominal NETs causing EAS
are, however, especially difficult to localize using ana-
tomical imaging techniques, and use of metabolic
modalities may be required. Jejunum location is extremely
rare among small bowels NETs causing EAS (14) (15) (16).3
J Ducry and others ACTH-secreting NETs unmasked
by F-DOPA-PET
ID: 14-0104; March 2015
DOI: 10.1530/EDM-14-0104SSRS, which was negative in our case, is expected to
identify NETs expressing high concentrations of cell
membrane SST2, for which octreotide displays selective
high-binding affinity. However, the sensitivity of SSRS in
EAS is relatively low, ranging from 25 to 60% (1) (13) (17),
suggesting low receptor expression in this syndrome
compared with other NETs. This could be an intrinsic
characteristic of tumors causing EAS, but a functional
mechanism consisting of selective downregulation of SST2
induced by elevated cortisol, can also been advocated. In
patients with primary adrenal insufficiency, somatostatin
administration resulted in more effective ACTH suppression
in patients left on low cortisol than on cortisol replacement
(18); in patients with Nelson’s syndrome, octreotide was
more efficient to lower ACTH, especially after temporary
withdrawal of cortisol replacement, than in patients with
Cushing’s disease and high cortisol levels (19); and exposure
to dexamethasone decreases the in vitro expression of SST2-
mRNA in pituitary adenoma cells (20). In this context, we
hypothesize that targeting the SST with pasireotide, a ligand
with high affinity for SST5, might result in better sensitivity
for occult EAS, knowing that the expression of SST5 mRNA
inpituitary adenoma corticotrophs is five- to ten-fold higher
than that of SST2 mRNA (21). Indeed, pasireotide is more
efficient than octreotide to control in vitro ACTH in the
presence of high levels of glucocorticoid (20), and was
proven to significantly decrease urinary cortisol excretion in
patients with Cushing’s disease (22). However, a similar
expression of SST5 in ectopic ACTH tumors and a similar
efficacy of pasireotide to treat EAS remain to be proven.
On the other side, SSRS using 68Gallium peptide receptor
radionucleides with octeotide derivatives were superior to
111Indium-Pentetreotide for NET detection (23), and 68Ga-
DOTA-TATE-PET, using octreotate, showed a high sensi-
tivity to detect well-differentiated metastatic NETs (24).
However, to our knowledge these radionucleides have not
been tested for occult EAS.
FDG-PET may highlight tumors with high metabolic
activity, but shows a low sensitivity (35%, CI 15–61%) to
identify NETs causing EAS (25). This examination was
negative in our case, possibly because of the low
proliferation index of the tumors.
F-DOPA-PET imaging is based on the ability of neuro-
endocrine cells to take up, accumulate, and decarboxylate
amine precursors for the synthesis of bioactive substances.
It has emerged as a diagnostic and staging tool for NETs, and
was of utmost importance to solve our case. Furthermore,
based from our case it can be hypothesized that the tumor
with hormone secretion required more precursor uptake
than the inactive one, possibly through upregulatedhttp://www.edmcasereports.commembrane transport systems: this would explain why the
ACTH-secreting tumor and its adjacent lymph-node meta-
stases were accurately identified with F-DOPA-PET, whereas
the neighboring nonsecreting NET remained silent, despite
the fact that both tumors had similarly low mitotic indexes.
Zemskova et al. (26) showed that of the 11 patients
with proven EAS but negative CT, MRI, and SSRS, the
F-DOPA-PET identified tumors in six patients, all of whom
had intra-thoracic NETs. This 55% sensitivity is lower than
the 69–96% sensitivity described for midgut or hindgut
carcinoids with no EAS (27) (28) (29), and suggests that
carcinoids take up DOPA more efficiently than nonsecret-
ing or ACTH-secreting NETs. However, the per-tumor-
positive predictive value of F-DOPA-PET in the small series
of intra-thoracic EAS was 100% (eight of eight tumors)
(26). We now show that F-DOPA-PET may constitute a
useful alternative to unveil occult EAS also in the less
frequent small intestine location.Conclusion
The optimal therapy of EAS remains surgical excision of
secreting tumor(s). However, small tumors causing EAS are
difficult to detect on anatomical imaging and may require
metabolic imaging techniques. We describe the case of a
64-year-old man presenting an occult EAS. The source of
the secretion remained undisclosed after CT-scan, MRI,
FDG-PET and SSRS. A small NET tumor causing EAS has
been finally unveiled with FDOPA-PET. Despite its rela-
tively low sensitivity, F-DOPA-PET should be considered as
a useful alternative to locate elusive tumors in occult EAS
when all other diagnostic modalities have failed.
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